The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Fair enough HT. Let's wait and see shall we.
Ssccss..but your opinion has no basis other than being a troll....Its so transparent it's hilarious
Thanks for the extracts Hulver. Be nice if HEMO had a bit more in the kitty but the report makes the situation clear
Keep it up folks; must be getting close to a new world record on here today.
https://www.youtube.com/watch?v=USh-hM_Nq4Q
If you stopped acting like we are in a playground but actually listened to alternative opinions, you might actually make some money.
Hemotruth you are really good at picking up half a story. I have bought and sold hemo since. I don't post all my activities. Honestly your powers of deduction need some work.
Exactly HT -
Company published results & Proactive investors are an investment organisation that highlight possible investments
& there current status etc etc & Vlad is at the spearhead of a science company doing great work & agreed to the interview to project Hemo & a potential investment & Proactive print the interview & facts - simple as they do with many companies every month .
Shorts / stock on loan
( which I only post to assist the invested for info purposes )
4.2 million opened @around 1.6 after the placement will be paying the cost to borrow daily so 6 weeks in , likely on a loss & sweating if a positive RNS drops .
The impatient sell & the small time Shorters try & fleece a few quid ,
However imo the investors with patience will be rewarded & Prevail certainly saw the potential otherwise why invest & get involved …
Noted by Prevail in Sept RNS
Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial."
Let’s see what next few months bring
And the Auditor's Assessment of the Board's views on going concern and teh next 18+ months:
P42: "Key Audit Matter: Going concern (Group and parent company – Note 2)
As part of our audit, we have performed the following procedures:
• Reviewed management’s assessment of going concern to 31 December 2025 and assessed the reasonableness of key assumptions and inputs used by management;
• Evaluated and corroborated the key assumptions and inputs underlying the budgets and cash flow forecasts, including sensitivity analysis against the base case scenario;
• Discussed with management how they intend to fund the clinical trials and other clinical programs, including an assessment of the funding options currently under negotiation;
• Compared management’s forecasts to actual results through the subsequent events period and performed inquiries to the date of this report;
• Assessed the probability of obtaining additional sources of funds when required, together with the ability to defer research and development expenditure; and
• Assessed the disclosures made regarding going concern in the financial statements for consistency with management’s assessment.
The group intends to progress its key development project to clinical trials together with the performance of other clinical programs. Significant additional funds will be required in order to progress as planned, which are not yet agreed and unconditional. As disclosed in Note 2, the group has a high proportion of discretionary expenditure which it is able to defer, if sufficient funding is not available. "
And just to emphasise some key words above:
"including an assessment of the funding options currently under negotiation."
Funding matters are being 'negotiated'. This to me still suggests Prevail led PIPE funding round.
From the Annual Report - the Company's view of the next 12 - 18 months:
"The Company successfully raised £5.25 million (before expenses) through the allotment and issue of new ordinary shares during the year ended 31 December 2023, and a further £3.25 million in early 2024. These proceeds were raised in order to facilitate the progression of the Company's HEMO- CAR-T product candidate into clinical trials and to enable the Company to continue development of product candidates for the treatment of viral infections and cancers based on its CBR platform.
Funding will be required by the Company to complete Phase I clinical development.
The Company cannot be certain that such additional funding will be available on acceptable terms, or at all. To the extent that the Company raises additional funds by issuing equity securities, the Company’s stockholders may experience dilution. Any debt financing, if available, may involve restrictive covenants. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to (i) significantly delay, scale back or discontinue the development and/or commercialisation of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favourable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that it would otherwise seek to develop or commercialise on unfavourable terms.
However, the Directors are of the opinion that the Company has adequate working capital to execute its operations for the present time and is confident in its ability to access additional financing over the next 12 months. The Directors, therefore, have made an informed judgement, at the time of approving these financial statements, that there is a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. As a result, the Directors have continued to adopt the going concern basis of accounting in preparing the annual financial statements. "
And on P27: Carrying value of investment in Hemogenyx Pharmaceuticals LLC
"The Committee reviewed the impairment assessment report prepared by management and agreed that given the reasonable expectation that the Group will achieve its milestone targets over the next 18 months no impairment to the value of the investment in Hemogenyx Pharmaceuticals LLC was required as at 31 December 2023."
He did the interview as the year end results had just been published...are you stupid as that's the second time you have asked that question, I see you sold hemo at 1.22p so your motive is clear.
A 4.2 million short @ 1.62 not underwater now
There's also the question of why Vlad did the recent interview... Maybe to help lift the sp... But for what reason? Not so traders could sell into it...
I think it's probably related to the fact the trial will take a long time and a raise will need to be made soon. So no there isn't much opportunity for news to lift the sp before a raise, so it will probably need to be at a discount IMO.
Seriously, £143.81k sells today.
Someone convince me this isn't symptomatic of something potentially very horrible on its way.
No, I'm not deramping or some sh*t like that. I'm an anxious LTH who would like to at least get his money back...!
Yup. some get bored I guess. Only 11m volume. You either believe trials will show positive results before year end or you dont. 52week range 1.1-7.13 so we know where this can go with a bit of positivity. GL holders
Cog got jammed today, why would anyone sell at these levels.
Morning all invested
Cogs will be turning
Prevail ain’t no naive muppets , they are a professional organisation who backed Hemos science & tossed a wedge in a lot higher than current stock price ,
I’m sure Vlad & Prevail are investigating all potential avenues for the benefit of Hemo & stockholders including Prevail .
Noted by Prevail in Sept RNS 👍
Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial."
Stock needs volume & positive news will bring volume & stock re rate imo .
To note -
Stock on loan / shorts
Current 4.3 million
a 200 k short was opened last week , I would guess a chancer hoping for bad news within the results - didn’t happen
& a 4.2 million short was opened 2 days after placement news @1.62
Currently underwater - unlucky 👎
So i am sceptical on any stock & any forums with negativity been posted with recent shorts opened , very risky in Hemo’s current position imo
Hemo are clinical & working with Prevail on CAR T 👍
With CBR & CDX cooking 👍
Good products will attract financial pharmas once news is confirmed. Imo 👍👍
Let’s see what next few months bring